Purpose: To describe spongiform scleropathy in a patient with oculodermal melanosis and without evidence of uveal melanoma. Methods: Clinical-pathological correlation conducted in compliance with HIPPA (Health Insurance Privacy and Portability Act) regulations. Results: Melanoma-associated spongiform scleropathy was an incidental finding in an 87-year-old woman with oculodermal melanocytosis treated for primary orbital melanoma. All previously reported cases of this scleropathy have been associated with uveal melanoma. Conclusions: The mechanism of scleral degeneration in melanoma-associated spongiform scleropathy is unknown, and its clinical and prognostic significance is speculative. This is the first case of a so-called melanoma-associated spongiform scleropathy reported in an eye without uveal melanoma.

Keywords:
Melanosis oculi, Nevus of Ota, Oculodermal melanosis, Scleral degeneration, Melanoma-associated spongiform scleropathy
1.
Alyahya GA: Melanoma-associated spongiform scleropathy: characterization, biochemical and immunohistochemical studies. Acta Ophthalmol 2008;86:1-21.
2.
Alyahya GA, Heegaard S, Prause JU: Characterization of melanoma associated with spongiform scleropathy. Acta Ophthalmol Scand 2002;80:322-326.
3.
Robert F: The sclera; in Heegaard S, Grosssniklaus HE (eds): Eye Pathology. Heidelberg, Spinger, 2015, chapt 4, pp 155-172.
4.
Alyahya GA, Ribel-Madesen SM, Heegaard S, Prause JU, Trier K: Melanoma-associated spongiform scleropathy: biochemical changes and possible relation to tumour extension. Acta Ophthalmol Scand 2003;81:625-629.
5.
Margo CE: Pigmented lesions of the eyelid; in Albert DM, Jakobiec FA (eds): Principle and Practice of Ophthalmology, ed 2. Philadelphia, Saunders, 2000, vol 4, chapt 257, pp 3430-3446.
6.
Singh AD, De Potter P, Fijal BA, Shields CL, Shields JA, Elston RC: Lifetime prevalence of uveal melanoma in white patients with oculo(dermal) melanocytosis. Ophthalmology 1998;105:195-198.
7.
Tellada M, Specht CS, McLean IW, Grossniklaus HE, Zimmerman LE: Primary orbital melanoma. Ophthalmology 1996;103:929-932.
8.
Lee V, Sandy C, Rose GE, Moseley IM, Cree I, Hungerford JL: Primary orbital melanoma masquerading as vascular anomalies. Eye 2002;16:16-20.
9.
Alyahya GA, Kolko M, Prause JU, et al: Matrix matalloproteinase-2 is expressed in melanoma-associated spongiform scleropathy. Invest Ophthalmol Vis Sci 2008;49:2806-2811.
10.
Weisbrod D, Pavlin CJ, McGowan H, Yucel YH: Clinical detection of melanoma-associated spongiform scleropathy by ultrasound biomicroscopy and its correlation with pathological diagnosis. Arch Ophthalmol 2009;127:1064-1066.
11.
Margo CE: Focal scleral mucinosis. Arch Ophthalmol 1986;104:806-807.
12.
Conn H, Green WR, de la Cruz ZC, Hillis A: Scleropachynsis maculopathy. Arch Ophthalmol 1982;100:793-799.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.